Regimen Disease status n ORR CR Survival Reference R-GEM High-grade B-NHL (elderly: 64–78 years) 7 (1 previously untreated) 71 % 29 % PFS:10 m [344] OS:11 m R-GEMOX Aggressive NHL…

Treatment Disease of EGC No. of enrolled patients Clinical response (CR/PR) Median survival (mos) References Cetuximab + FOLFOX/RT + surgery E, ESCC 41 8/12 17 [43] Cetuximab + cisplatin/docetaxel/RT +…

86. Rao H-L, Chen J-W, Li M, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One. 2012;7:e30806.PubMedCentralPubMed 87. Algars…

Stage Immune phenotype Target Early precursor HLA-DR, TdT, cCD22, CD79a, CD19 CD19 Blinatumomab Intermediate precursor (common) HLA-DR, TdT, cCD22, CD79a, CD19, CD10, CD20 (variable) CD19 Blinatumomab CD20 Rituximab, ofatumumab Late…

62. Scursoni AM, Galluzzo L, Camarero S, Pozzo N, Gabri MR, de Acosta CM, et al. Detection and characterization of N-glycosylated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol….

Mechanism Ag Short description of function Ab name Results of earlier trials Ongoing clinical trials mAbs targeting proteins involved in myeloma cell adhesion CS1 See text Elotuzumab   Syndecan-1 (CD138) Cell…

1 Shared/self-/differentiation TAAs (e.g., Melan-A, PSA, CEA) 2 Shared/self-/cancer testis or germinal TAAs (e.g., MAGE, NY-ESO-1) 3 Universal TAAs (e.g., survivin, hIERI) 4 Mutated, unique TAAs The TAAs recognized by…

Fig. 7.1 The figure demonstrates the immune environment of HRS cells in HL, as well as the antibodies located on the cell surface which are considered potential targets for immunotherapy…

Fig. 5.1 Models of pathogenesis of AML. Three possible scenarios for the development of the LSC are shown. Hematopoietic stem cells (HSC) or myeloid progenitors (MP) or both populations are…